Corpus Intelligence IC Memo — CASTLEVIEW HOSPITAL 2026-04-26 05:27 UTC
IC Memo — CASTLEVIEW HOSPITAL
Investment Committee Memorandum | UT | 39 beds | Grade C | EBITDA uplift $6.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CASTLEVIEW HOSPITAL

CCN 460011 | CARBON, UT | 39 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CASTLEVIEW HOSPITAL is a 39-bed suburban community hospital in CARBON, UT with $84.5M in net patient revenue and a 21.5% operating margin. The hospital serves a payer mix of 40.4% Medicare, 20.3% Medicaid, and 39.4% commercial.

Thesis: Turnaround. Our ML models identify $6.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 21.5% to 28.8% (+736bps).

Net Revenue HCRIS$84.5M
Current EBITDA COMPUTED$18.1M
Operating Margin COMPUTED21.5%
Occupancy HCRIS30.3%
Revenue / Bed COMPUTED$2.2M
Net-to-Gross HCRIS35.5%
Distress Probability ML56.2%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
24
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of 21.5% places it above the state median. Among 24 size-comparable peers (20-78 beds), the median margin is 3.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-78), prioritizing same-state peers. 24 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CASTLEVIEW HOSPITAL (Target)UT39$84.5M21.5%
CEDAR CITY HOSPITALUT48$136.8M31.4%
LONE PEAK HOSPITALUT61$133.1M25.2%
ALTA VIEW HOSPITALUT57$130.9M-0.6%
GUNNISON VALLEY HOSPITALUT25$130.4M-6.4%
LAYTON HOSPITALUT37$121.1M9.5%
PARK CITY HOSPITALUT37$120.8M13.7%
UINTAH BASIN MEDICAL CENTERUT33$119.9M1.8%
MOUNTAIN WEST MEDICAL CENTERUT36$96.1M38.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.8M+210bp18mo
Cost to Collect4.5%2.5%$1.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.0M+122bp9mo
Clean Claim Rate88.0%96.0%$54K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.8M
Cost to Collect
$1.7M
Denial Rate Reduction
$1.7M
A/R Days Reduction
$1.0M
Clean Claim Rate
$54K
Total EBITDA Uplift$6.2M
Current EBITDA$18.1M
+ RCM Uplift+$6.2M
Pro Forma EBITDA$24.3M
Current Margin21.5%
Pro Forma Margin28.8%
WC Released (1x)$3.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$27.9M$181.8M6.52x45.5%
Base (11x exit)10.0x11.0x$27.9M$209.0M7.49x49.6%
Bull Case9.0x11.0x$25.1M$238.6M9.50x56.9%
Bull (12x exit)9.0x12.0x$25.1M$267.7M10.66x60.5%
Bear Case11.0x10.0x$30.7M$141.6M4.62x35.8%
Bear (11x exit)11.0x11.0x$30.7M$165.8M5.40x40.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 30.3%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 56.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 24 hospitals with 20-78 beds
  • Same-state prioritization (n=25)
  • Comp margins: P25=-12.6% / P50=3.0% / P75=13.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.